As of 2025-11-18, the Intrinsic Value of InDex Pharmaceuticals Holding AB (INDEX.ST) is 91.07 SEK. This INDEX.ST valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 45.30 SEK, the upside of InDex Pharmaceuticals Holding AB is 101.00%.
The range of the Intrinsic Value is 22.64 - 250.68 SEK
Based on its market price of 45.30 SEK and our intrinsic valuation, InDex Pharmaceuticals Holding AB (INDEX.ST) is undervalued by 101.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (10,941.09) - (1,439.70) | (2,426.12) | -5455.7% |
| DCF (Growth 10y) | (841.42) - (4,756.75) | (1,252.33) | -2864.5% |
| DCF (EBITDA 5y) | 22.64 - 250.68 | 91.07 | 101.0% |
| DCF (EBITDA 10y) | (30.70) - 270.82 | 60.54 | 33.6% |
| Fair Value | -0.53 - -0.53 | -0.53 | -101.17% |
| P/E | (100.32) - (116.79) | (108.97) | -340.6% |
| EV/EBITDA | 4.86 - 131.34 | 59.21 | 30.7% |
| EPV | (142.36) - (200.38) | (171.37) | -478.3% |
| DDM - Stable | (179.14) - (1,937.05) | (1,058.09) | -2435.7% |
| DDM - Multi | (193.09) - (1,619.72) | (344.73) | -861.0% |
| Market Cap (mil) | 245.35 |
| Beta | -0.92 |
| Outstanding shares (mil) | 5.42 |
| Enterprise Value (mil) | -22.42 |
| Market risk premium | 5.10% |
| Cost of Equity | 6.25% |
| Cost of Debt | 5.00% |
| WACC | 6.22% |